Since it launched Choose You in May 2010, the American Cancer Society has motivated more than 75,000 people, most of them women, to put their health at the top of their to-do lists. Choose You raises awareness about the simple actions people can take that can significantly reduce their risk of cancer, and reminds people of the sobering statistic that one in three women will get cancer in her lifetime. The Society urges women to join the movement at ChooseYou.com to help change the odds.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/cancer/50026/
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that the Light Study, a long-term research study of Contrave® (naltrexone SR/bupropion SR), a new, investigational drug being evaluated for weight loss, has begun enrolling patients at clinical sites throughout the United States. The Light Study is designed to assess the cardiovascular health outcomes of Contrave.
Nearly 93 million Americans are affected by obesity, and that number is predicted to increase to 120 million Americans within the next five years. More than one-third of adults in the United States are affected by obesity. Obesity increases the risk of heart disease, type 2 diabetes, some types of cancer, sleep apnea, and a variety of other conditions. Medical research suggests that losing just five percent of your body weight can significantly improve your health and reduce the risk of complications from type 2 diabetes and heart disease.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56480-lightstudy
I feel fabulous, not flabulous, how about you? Check me and The Buttons out as we Get Waisted. In line with our single release, Mama Mio will give a donation for every Get Waisted sold through http://www.mamamio.com/uk/belle-and-t... or through Debenhams to cancer support charity Look Good...Feel Better.
EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced the opening of a state-of-the-art research center in Billerica, MA, establishing it as a “hub” within the Merck KGaA research organization. Representing a $65 million investment, the Billerica research facility supports the company’s commitment to developing and discovering innovative treatments in oncology, neurodegenerative diseases and infertility. Nearly 100 new jobs will be added in Massachusetts as a result of the building expansion.
To view Multimedia News Release, go to
http://multivu.prnewswire.com/mnr/emdserono/48166/
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
Researchers studying the genetic roots of the most common malignant childhood brain tumor have discovered missteps in three of the four subtypes of the cancer that involve genes already targeted for drug development.
At its annual meeting of more than 10,000 financial representatives and staff members today, Northwestern Mutual announced its new multi-year philanthropic program to fight childhood cancer. The effort, through the Northwestern Mutual Foundation, builds upon the company’s legacy of helping children and families. It leverages Northwestern Mutual’s field force throughout the country to implement a range of community events and programs to raise awareness and money for pediatric cancer.
To view Multimedia News Release, go to http://www.multivu.com/mnr/53645-northwestern-mutual-philanthropic-campaign-pediatric-cancer-research
Nearly five black women die needlessly per day from breast cancer in the United States – a total of 1,722 deaths annually – according to a study released today at the Avon Foundation Breast Cancer Forum and simultaneously published in Cancer Epidemiology. The 2012 Racial Disparity in Breast Cancer Mortality Study found that 21 of the 25* largest U.S. cities have a black: white disparity in breast cancer mortality, 13 of which are statistically significant.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52895-avon-foundation-breast-cancer-forum-racial-disparity-mortality-study
Mimi’s Cafe® announces its partnership with National Breast Cancer Foundation (NBCF) and launches the Mimi’s Power of Pink campaign in October, Breast Cancer Awareness Month. All 145 Mimi’s locations will raise awareness and funds in support of NBCF’s mission to save lives through early detection and by providing mammograms for women in need. Mimi’s kicks off the campaign Oct. 1 with a special offer: Wear pink to Mimi’s and receive a FREE seasonal Pumpkin Spiced Muffin with any purchase. There will be more ways to participate throughout the month.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58344-mimi-s-cafe-power-of-pink-national-breast-cancer-awareness-month-october
Researchers have identified the first gene mutation associated with a chronic and often fatal form of neuroblastoma that typically strikes adolescents and young adults. The finding provides the first clue about the genetic basis of the long-recognized but poorly understood link between treatment outcome and age at diagnosis.
The study involved 104 infants, children and young adults with advanced neuroblastoma, a cancer of the sympathetic nervous system. Investigators discovered the ATRX gene was mutated only in patients age 5 and older. The alterations occurred most often in patients age 12 and older. These older patients were also more likely than their younger counterparts to have a chronic form of neuroblastoma and die years after their disease is diagnosed.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52992-st-jude-pediatric-cancer-genome-project-neuroblastoma-research
Researchers have discovered that a subtype of leukemia characterized by a poor prognosis is fueled by mutations in pathways distinctly different from a seemingly similar leukemia associated with a much better outcome. The findings from the St. Jude Children’s Research Hospital — Washington University Pediatric Cancer Genome Project (PCGP) highlight a possible new strategy for treating patients with this more aggressive cancer.
The work provides the first details of the genetic alterations fueling a subtype of acute lymphoblastic leukemia (ALL) known as early T-cell precursor ALL (ETP-ALL). The results suggest ETP-ALL has more in common with acute myeloid leukemia (AML) than with other subtypes of ALL. The study appears in the January 12 edition of the journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46768-st-jude-cancer-genome-sequencing-project-combat-aggressive-leukemia
